Formulation and evaluation of transdermal patch of stiripentol for treatment of seizures

https://doi.org/10.54037/WJPS.2021.91005

Abstract

Dravet syndrome is identified as sever myoclonic epilepsy in infancy. It is characterized as behavioural deterioration or regression together with the cognitive decline due to epileptogenic activity during maturation period. The primary treatment for the Dravet syndrome is generally valproic acid and clobazam. Stiripentol is a drug which acts in the both directly by inhibiting GABA_A receptor and indirectly by inhibiting Valproic acid and clobazam metabolism to control the seizures in Dravet syndrome. As it is insoluble in water results into the poor bioavailability and therefore coming up with the transdermal patch as a sustainable dosage form is necessary. It is bit of a hustle to feed the babies with the regimen. So, formulation of transdermal patch results into better bioavailability and avoid the hustle of feeding the babies with better seizure management. Here we have used HPMC and PVP as the matrix forming polymers to facilitate the sustained release and the evaluations were done.